The companies at the frontier of artificial intelligence should be ready to slow down, one of the fastest-moving among them says. Anthropic, the maker of the Claude chatbot, has claimed AI systems may ...

RSI is also defined as an “AI system capable of fully autonomously designing and developing its own successor,” per Anthropic’s blog post. “We are not there yet, and recursive self-improvement is not ...

Recursive Superintelligence has raised $650 million at a $4.65 billion valuation in a funding round led by GV and Greycroft, according to the company. The round also included participation from AMD ...

Recursive Superintelligence Inc., a startup that hopes to develop self-improving artificial intelligence models, launched today with $650 million in funding. Alphabet Inc.’s GV fund and Greycroft led ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. logos of OpenAI There’s interesting news coming from Sam Altman’s empire, a firm known for ...

The former rugby union player had spoken publicly about the belief he was suffering from CTE. Joe Allison / Getty Images Former rugby union player and brain injury activist Shane Christie has been ...

New York Giants running back Cam Skattebo's has apologize for comments he made in a surreal interview earlier that week where he said CTE was fake. Skattebo, who's entering his second season in the ...

Cam Skattebo has earned a reputation for being a hard-nosed running back, and now it's easy to see why. The New York Giants running back became a rookie phenom last season, scoring seven touchdowns in ...

Maybe Cam Skattebo should stick to eating crayons. Appearing recently on the Bring the Juice with Frank Dalena podcast, the Giants running back had some things to say about Chronic Traumatic ...

Forbes contributors publish independent expert analyses and insights. John Sviokla covers GenAI/AI's impact on commerce and society. This voice experience is generated by AI. Learn more. This voice ...

SALT LAKE CITY, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...

The consensus mark for RXRX's Q4 loss and sales are pinned at 28 cents per share and $25.5M, respectively. In late 2025, RXRX highlighted REC-4881 data showing rapid, durable polyp reductions in FAP ...